… pulmonary exacerbations in CF. In this review, the efficacy and safety of the currently available
inhaled antibiotics … Moreover, the effects of long-term inhaled antibiotic therapy for chronic …

… The first report of inhaled antibiotic use in CF appeared in the … use of inhaled antibiotics in
the CF population. The development of inhaled antibiotics has primarily focused on antibiotics …

… In conclusion, to definitively recommend treatment algorithms for inhaled antibiotics in
non–cystic fibrosis bronchiectasis large-scale, long-term controlled studies are needed. …

… inhaled antibiotics only after patients have suffered repeated exacerbations despite appropriate
use of chronic macrolides, aerosolized … trial of nebulized gentamicin in non-cystic fibrosis …

… Inhaled antibiotics have been used for a long … inhaled antibiotics in NCFB patients.
Furthermore, we will address potential future challenges in the widespread use of inhaled antibiotics, …

… In summary, dornase alfa, hypertonic saline, and mannitol are inhaled agents that have
each been shown to demonstrate pulmonary benefits in CF by improving mucus clearance, …

… inhaled antibiotics for the treatment of pulmonary exacerbations in people with cystic
fibrosis… trial of inhaled antibiotics for the management of pulmonary exacerbations (NCT03066453). …

… with inhaled antibiotics, most commonly tobramycin, aztreonam and colistin. Deposition
patterns of inhaled antibiotics … However, after deposition in the airways, the antibiotic must first …

… Additionally, inhaled liposomal amikacin and murepavadin are … inhaled antibiotics will
be summarized. Combination therapy and the strategies to select an optimal inhaled antibiotic …

… Experience with using inhaled antibiotics has varied. Aerosolized antibiotics have been …
patients with cystic fibrosis, tuberculosis, non-cystic fibrosis bronchiectasis, or COPD (Table 2). …